Search PubMed⌕ Search

PubMed · 7678870

Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation.

Abstract

We measured the maximum urinary flow rate monthly for 1 year by uroflowmetry in 1,645 patients in a double-blind, placebo-controlled study of finasteride therapy for benign prostatic hyperplasia. Patients were randomized to receive placebo (555) or finasteride (1,090). A total of 23,857 flow measurements was obtained. Because of the presence of artifacts on many uroflow curves, we read the maximum urinary flow rate values manually and compared them to the values provided electronically by the uroflowmeter. On average, the manually read values were 1.5 ml. per second lower than the machine read values. Artifacts causing a difference of 2 ml. per second or more between the 2 methods were found in 20% and of more than 3 ml. per second in 9% of the tracings. The difference between treatment groups in mean maximum urinary flow rate change at the end of the study was the same with both reading methods. However, confidence intervals were 15 to 25% larger for the machine read compared to the manually read values. This larger variability in machine read maximum urinary flow rate has a marked negative impact on the power of statistical tests to assess any given difference in maximum urinary flow rate between treatment groups. Furthermore, it increases sample size requirements by 50% to achieve any given statistical power. We conclude that maximum urinary flow rate artifacts contribute significantly to the variability of maximum urinary flow rate measurement by uroflowmetry. Manual reading of the maximum urinary flow rate eliminates an important fraction of such variability.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P B Grino, R Bruskewitz, J G Blaivas, M B Siroky, J T Andersen, T Cook, E Stoner. 1993. Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation.. https://doi.org/10.1016/s0022-5347(17)36076-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial.

BACKGROUND: Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA). When men taking this treatment undergo screening for prostate cancer, a compensatory adjustment of the PSA concentration (to multiply the value by two) is recommended. Whether this recommendation should apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown. We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss. METHODS: Between March 13, 1998, and Jan 12, 2000, 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and 50-60 years), and randomised in a ratio of four to one to 1 mg/day finasteride or placebo. The primary endpoint was the effect of this treatment for 48 weeks on serum PSA concentration compared with placebo. This trial is in the process of being registered on the US National Institutes of Health website . Analyses were according to protocol. FINDINGS: Within 48 weeks of randomisation, men aged 40-49 years and 50-60 years who were assigned 1 mg/day finasteride had a median decrease in serum PSA concentration of 40% (95% CI 34-46) and 50% (44-57), respectively. In men assigned placebo, the median changes were 0% [-14 to 14] and a median increase of 13% [2 to 24], respectively. INTERPRETATION: In men aged 40-60 years, 1 mg/day finasteride for 48 weeks lowers serum PSA concentration. Therefore, the existing recommendation for the adjustment of serum PSA concentration in prostate-cancer screening in men taking 5 mg/day finasteride should also apply to men taking the 1 mg/day preparation for male-pattern hair loss. Research is needed to assess the effect of 1 mg/day finasteride preparation beyond 48 weeks of treatment.

5-alpha Reductase Inhibitors↗

The anxiolytic effect of pregnancy in rats is reversed by finasteride.

Several studies have shown the influence of the oestrous cycle on anxiety levels and the important role of progesterone in this effect. The metabolism of this steroid hormone yields neuroactive steroids among them allopregnanolone (alloP) and allotetrahydrodeoxycorticosterone (alloTHDOC), which bind to GABAA receptors and have anxiolytic effects. Considering that during pregnancy there is an increase in levels of both progesterone and its metabolites, the main objectives of this work were: (1) to assess changes in anxiety levels during pregnancy and (2) to verify the role of alloP and alloTHDOC in this process using finasteride, an inhibitor of 5alpha-reductase, the enzyme responsible for their synthesis. The results showed a significant reduction in anxiety levels on the 19th day of pregnancy, which was reversed by finasteride, suggesting a role for alloP and alloTHDOC in the anxiolytic process.

5-alpha Reductase Inhibitors↗